Mineralys Therapeutics (NASDAQ:MLYS – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a report issued on Thursday,Benzinga reports. They currently have a ...

Mineralys Therapeutics (NASDAQ:MLYS – Get Free Report) had its price objective reduced by research analysts at The Goldman Sachs Group from $28.00 to $24.00 in a research note issued to investors on ...

Q4 2024 Earnings Call Transcript February 12, 2025 Mineralys Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

Anticipate topline data from pivotal Advance-HTN trial in March 2025 and pivotal Phase 3 Launch-HTN trial in mid first half of 2025 –– ...

In a report released today, Richard Law CFA from Goldman Sachs maintained a Buy rating on Mineralys Therapeutics, Inc. (MLYS – Research ...

Q4 2024 Management View CEO Jon Congleton highlighted the company's focus on advancing its pivotal trials for lorundrostat, targeting dysregulated aldosterone in patients with uncontrolled and ...

I believe Mineralys Therapeutics has a promising candidate with Lorundrostat for hypertension, CKD, and OSA. It should report more key pivotal clinical data this year. MLYS has several Phase 2 and ...

(RTTNews) - Mineralys Therapeutics, Inc. (MLYS), a clinical-stage biopharmaceutical company focused on developing treatments for hypertension and chronic kidney disease or CKD, on Tuesday ...

Mineralys Therapeutics, Inc. (MLYS) stock price is 10.30 and Mineralys Therapeutics, Inc. (MLYS) 10-day simple moving average is 10.02. Mineralys Therapeutics, Inc. (MLYS) stock price is 10.30 and ...

Ericsson Posts Weak Results, Joins East West Bancorp And Other Big Stocks Moving Lower In Friday's Pre-Market Session ...

Jon Congleton; Chief Executive Officer, Director; Mineralys Therapeutics Inc. David Rodman; Chief Medical Officer ...